Omixon Biocomputing Ltd is sponsoring PTx Session 6 – Personalized Therapeutics

02/12/2022

We are happy to announce that Omixon Biocomputing Ltd is sponsoring PTx Session 6, Personalized Therapeutics! The Personalized Therapeutics session will be moderated by Amanda Cunningham from UBC, and it takes place on Tuesday, December 13th starting at 11 am.

Omixon Launches NanoTYPE^TM RUO, a Multiplex Human Leukocyte Antigen Amplification kit compatible with Oxford Nanopore’s MinION^TM Platform and Enters into an Agreement with Oxford Nanopore Technologies

26/09/2022

High resolution histocompatibility testing for urgent transplant cases made possible within five hours turnaround time. Budapest, Hungary, September 27, 2022. Omixon Biocomputing, Ltd announced today the launch of NanoTYPE^TMRUO, a multiplex 11 loci human leukocyte antigen (HLA) amplification kit and the complementary NanoTYPER^TMsoftware compatible with Oxford Nanopore’s...

Editorial Board Award – Human Immunology

10/05/2022

Each year, the Human Immunology editorial board awards the best original research papers and the best review papers from two years previous. The top papers in each category published in 2020 were chosen based on citation and download statistics gathered from 2021. The papers were then voted on by...

Doug Bost became a member of the Scientific Advisory Board for Digital PCR at QIAGEN

10/05/2022

Omixon is entering the field of post-transplant monitoring. To ensure its position in the market our company has entered a strategic partnership with Organ Monitoring Group (OMG) founded by Doug Bost to bring our newest product, HoloGRAFT, to market. Doug Bost joined Omixon in the position of VP of...

NanoTYPE HLA – A New Era of HLA Typing

10/05/2022

Written by Libor Kolesár, PhD HLA tissue typing is like a constantly changing and evolving organism. During the era of SSP and SSOP methods, Sanger-based typing (SBT) was developed and quickly became the gold standard. SBT had several advantages over SNP-based methods (SSP and SSOP) as it was not...